Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

Documenti analoghi

• Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
  di: Nishimoto, Norihiro, et al.
  Pubblicazione: (2008)
• Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
  di: Ogata, Atsushi, et al.
  Pubblicazione: (2014)
• Study of active controlled monotherapy used for rheumatoid arthritis, an IL‐6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader‐blinded randomised controlled trial of tocilizumab
  di: Nishimoto, Norihiro, et al.
  Pubblicazione: (2007)
• Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials
  di: Takeuchi, Tsutomu, et al.
  Pubblicazione: (2015)
• Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
  di: Ogata, Atsushi, et al.
  Pubblicazione: (2015)